CKM and chronic kidney disease: The combination of SGLT2i and GLP-1RA may result in complementary benefits, given the confluence of CKM factors and the high total CVD risk, which is also supported by KDIGO CKD 2024,17 although randomized control trial evidence for dual use is not yet published.